This story is an interesting twist to the usual health news article reviewed on this site. It comes from a regular column, "The Unreal World," in the LA Times that reviews health issues in prime time TV shows. The story provides an overview of a recent episode of a popular TV show – Boston Legal (ABC, Dec 1) and then addresses the clinical content of the show in a point-by-point manner. The episode continues a story line about a lead character Denny Crane, played by William Shatner, who has been diagnosed with mild to moderate Alzheimer’s disease. Crane/Shatner’s memory loss is progressing so he takes legal action (all the way to the supreme court) to gain access to an experimental drug which has not been approved by the Food and Drug Administration (FDA). The aspects of this dramatization related to Alzheimer’s disease symptoms and stages, PET scans of the brain, the experimental drug Dimebon, and the FDA approval drug approval process are accurate. The article is well organized, raising and summarizing the relevant clinical issues, addressing the medical questions in depth and evaluating their portrayal in the TV show. The column omits some basic information we wish it had included such as quantifying the benefits seen with Dimebon, something on the harms seen with it, and a reminder that available medications for Alzheimer’s can help a small number of people but only for a limited amount of time.
The cost of the drug is not particularly relevant in this case.
This story points out the potential benefits of Dimebon based upon preliminary research, but didn’t quantify those benefits. These include improved cognition, memory and ability to perform activities of daily living. These potential benefits should have been placed in the context of existing medications which have shown a very modest effect in these outcomes, in only one-third of people, and for a short-period of time. Little is know about the long-term use of these medications.
The story references general concerns of experimental drugs which do not have proven effectiveness or safety. Potential harms of Dimebon were not mentioned. However, the research study about the Dimebon published in The Lancet reported that dry mouth was the most common side effect. For reference, there can be gastrointestinal side effects from currently approved medications. These are usually dose related and can be minimised by taking the medications with food and gradually increasing the dose overtime.
This story takes a point-by-point approach to evaluate the medical issues related to Alzheimer’s disease raised in the TV episode. The Premise section provides a good, basic description of PET scan brain imaging and symptoms of mild to moderate memory loss. The story should have clearly noted that PET scans do not provide a definitive diagnosis and that tests to evaluate memory such as questionnaires and neurological examinations, are routinely performed as the first line of evaluation. The piece does provide an appropriate level of depth in its discussion of the experimental nature of Dimebon, results of research conducted in Russia, and the stages of the FDA approval process.
Basics facts about the prevalence of Alzheimer’s disease were not provided, but would have helped readers to understand how many people are affected (about 15% over 70 years old). Given that, Alzheimer’s disease was accurately characterized in the story.
The story includes interviews from an independent medical expert and the chief medical officer for the Alzheimer’s Association (www.alz.org).
This story could have been enhanced by adding that there are currently no cures for Alzheimer’s disease. It should have noted that available medications can help a small number of people but only for a limited amount of time.
This story clearly indicates that the experimental drug Dimebon is not available in the U.S. It also notes that the drug won’t be available for at least three years, pending FDA approval.
The story indicates that Dimebon is a new and experimental drug to treat Alzheimer’s disease.
This story does not rely on a press release.
Systematic, Criteria-Driven
We’ve written about the hype of liquid biopsies for years (see link in comment below). And now this…. https://www.statnews.com/2022/01/12/medicare-shouldnt-cover-liquid-biopsies-early-cancer-detection/
Case counts still matter. “(There) are stories that may not be told adequately if only hospitalizations and deaths are emphasized.” @garyschwitzer interviewed by @dbauder of @AP. https://apnews.com/article/omicron-changing-news-outlets-covid-data-da9272f7c4c8a109c3bfb56bed9e9c76
My friend Gary @garyschwitzer wrote to his city council representative in a Minnesota town about a Viva Las Vegas event scheduled for January.
The response he got seems to perfectly capture where we are now.
https://www.healthnewsreview.org/2021/12/2021-ends-with-covid-craziness-in-sports-and-politics/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like